Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195299 · ClinicalTrials.gov registry record
Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck
A clinical trial of Squamous Cell Carcinoma, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT00195299 is a study of Squamous Cell Carcinoma that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 20 participants, below the 104-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00195299, a study of Squamous Cell Carcinoma, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, exploratory, biomarker study of intravenous temsirolimus given once weekly for 3 weeks to newly diagnosed, advanced stage head and neck cancer subjects prior to beginning their standard therapy for their specific disease. The primary objective of this study is to identify biomarkers of temsirolimus activity.
Conditions Studied
Interventions
- DRUG Temsirolimus
Study Locations (1)
Louisiana
- - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00195299
The ClinicalTrials.gov registry entry for NCT00195299 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (81% lower). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Temsirolimus is the first listed.
NCT00195299 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT00195299 about?
NCT00195299 is a clinical study titled "Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck". This is an open-label, exploratory, biomarker study of intravenous temsirolimus given once weekly for 3 weeks to newly diagnosed, advanced stage head and neck cancer subjects prior to beginning their standard therapy for their specific disease. The primary objective of this study is to identify biom...
What is the current status of trial NCT00195299?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2005-04. Estimated completion is 2007-02.
What conditions does trial NCT00195299 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma.
What interventions are being tested in trial NCT00195299?
The interventions under investigation include: Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00195299?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00195299 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
RECRUITING · Phase 2
-
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
RECRUITING · NA
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
RECRUITING · Phase 2
-
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
RECRUITING · Phase 1
-
Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain
RECRUITING · NA
-
Toripalimab With Chemotherapy for Sinus Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.